Ensysce Biosciences


MPAR™  Overdose Resistant Technology

MPAR™ Technology

Our MPAR™ overdose resistant technology is being developed in parallel with TAAP.  A follow-on product to PF614 is in late preclinical development and clinical evaluation in an early Phase 1 trial has demonstrated the utility of the MPAR™ approach. Ensysce’s extensive patent portfolio covers MPAR™ products internationally.